Evidence map›Paper›PMID 40772932›Full record

ArticleMicrobiology spectrum2025

Antibiotic tolerance and persistence in clinical isolates of

N R Alexandersen, K L Nielsen, S Häussler, T Bjarnsholt, K Schønning

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Pyocyanin produced byAntimicrobial agents and chemotherapy · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

N R AlexandersenDepartment of Clinical Microbiology, Copenhagen Universisty Hospital, Rigshospitalet, Copenhagen, Denmark.
K L NielsenDepartment of Clinical Microbiology, Copenhagen Universisty Hospital, Rigshospitalet, Copenhagen, Denmark.
S HäusslerTwincore, Center for Experimental and Clinical Infection Research, a Joint Venture of the Helmholtz Centre for Infection Research and the Hannover Medical School, Braunschweig, Germany.
T BjarnsholtDepartment of Clinical Microbiology, Copenhagen Universisty Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-8003-7414
K SchønningDepartment of Clinical Microbiology, Copenhagen Universisty Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-7767-305X

Funding

Grosserer L. F. Foghts Fond LF22.210
6 · The paper itself

Abstract

Bacteria showing tolerance to antibiotic killing are characterized by a slower kill rate compared with other isolates from the same species. Antibiotic persistence is defined by a subpopulation of bacteria showing a reduced kill rate when an isolate is exposed to a bactericidal antibiotic. Both are best studied using time-kill experiments and have been associated with treatment failure and the development of antibiotic resistance. Despite their potential clinical importance, quantitative data for the variation in antibiotic tolerance and persistence are lacking. Here, we performed time-kill experiments using 15 clinical

Indexed as

Anti-Bacterial AgentsEscherichia coliEscherichia coli Infectionsbeta-LactamasesCiprofloxacinDrug Resistance, BacterialHumansMeropenemMicrobial Sensitivity TestsMicrobial ViabilityAnti-Bacterial Agentsbeta-LactamasesCiprofloxacinMeropenembeta-lactamsEscherichia colimathematical modelingpersistencequinolonestime-kill curvestolerance

Identifiers

PMID40772932
PMCPMC12403604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.